SCHEMBL351304

SCHEMBL351304

NC(=O)C1C2C=CC(C2)C1Nc1[nH]c(Nc2ccc(OCCN3CCCC3)c(Cl)c2)nc2ncnc1-2

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 7/20 0.51
MAP3K7 O43318 4/20 0.51
ALK Q9UM73 4/20 0.40
INSR P06213 4/20 0.40
MET P08581 1/20 0.39
KDR P35968 3/20 0.39
AURKB Q96GD4 2/20 0.39
AXL P30530 1/20 0.39
ERBB2 P04626 2/20 0.39
AURKA O14965 1/20 0.39
EGFR P00533 1/20 0.38
BACE1 P56817 2/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL351751 0.92 IRAK4 (0.51) IRAK4MAP3K7ALKINSRMET
SCHEMBL351381 0.88 IRAK4 (0.59) IRAK4MAP3K7KDRAURKB
SCHEMBL352258 0.82 IRAK4 (0.45) IRAK4MAP3K7ALKINSRKDR
SCHEMBL1325549 0.82 IRAK4 (0.45) IRAK4MAP3K7ALKINSRKDR
SCHEMBL352581 0.82 IRAK4 (0.45) IRAK4MAP3K7ALKINSRKDR
SCHEMBL1305373 0.79 INSR (0.43) IRAK4MAP3K7ALKINSRCYP3A4
SCHEMBL1306923 0.79 IRAK4 (0.42) IRAK4MAP3K7ALKINSRMET
SCHEMBL10171322 0.78 IRAK4 (0.60) IRAK4MAP3K7ALKINSRMET
SCHEMBL352214 0.78 IRAK4 (0.62) IRAK4MAP3K7ALKINSRMET
SCHEMBL4792817 0.77 AURKB (0.41) IRAK4MAP3K7ALKINSRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960372-B1 KINASE INHIBITORS AND THEIR USES RIGEL PHARMACEUTICALS INC (US) 2015-12-09 EP claimed
US-9834568-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2017-12-05 US disclosed
US-20160024116-A1 Kinase Inhibitors And Their Uses MIDCAP FINANCIAL TRUST 2016-01-28 US disclosed
EP-1960372-B1 KINASE INHIBITORS AND THEIR USES RIGEL PHARMACEUTICALS INC (US) 2015-12-09 EP disclosed
US-9096542-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2015-08-04 US disclosed
US-20120015937-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2012-01-19 US disclosed
US-8053434-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2011-11-08 US disclosed
US-20100069369-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2010-03-18 US disclosed
US-7601713-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
US-20070142402-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015937-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN IRAK4 239/4885MAP3K7 36/4885ALK 230/4885
US-20160024116-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN IRAK4 239/4885MAP3K7 36/4885ALK 230/4885
US-20100069369-A1 Kinase Inhibitors And Their Uses BTK, SYK, JAK2 IRAK4 293/4885MAP3K7 24/4885ALK 221/4885
US-20070142402-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN IRAK4 239/4885MAP3K7 36/4885ALK 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.